More ‘biosimilar’ medicines should be brought to market in the EU because of a regulatory policy shift on the need to carry out expensive clinical efficacy studies, experts have said.

Marlén Mendoza is a queer-identifying coffee roaster and co-founder of Ema HTX, a Michelin Bib Gourmand-awarded breakfast ...

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...

The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

The EMA’s Committee for Medicinal Products for Human Use said that a phase 3 study in children aged 3-14 years demonstrated ...

The European Medicines Agency’s (EMA’) human medicines committee (CHMP) has recommended two new medicines and three ...

Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 ...

PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted full qualification for ...

The Continental pilot was launched in November 2023, with the technical support of the European Medicines Agency (EMA), World Health Organization (WHO) and other partners. For many years, Africa has ...